We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Artificial Editing Technique Modifies Gene Activity

By LabMedica International staff writers
Posted on 16 May 2017
Print article
Image: Neurons from Angelman syndrome (AS) patients lack expression of the UBE3A protein due to an epigenetic defect. The photomicrograph shows that a new method restored normal expression of the UBE3A protein in neurons derived from the cells of an AS patient by correcting the aberrant methylation pattern (Photo courtesy of the Salk Institute for Biological Studies).
Image: Neurons from Angelman syndrome (AS) patients lack expression of the UBE3A protein due to an epigenetic defect. The photomicrograph shows that a new method restored normal expression of the UBE3A protein in neurons derived from the cells of an AS patient by correcting the aberrant methylation pattern (Photo courtesy of the Salk Institute for Biological Studies).
A team of molecular biologists has developed an artificial epigenetic editing technique that adds methyl groups to DNA and modifies specific gene activity in a hereditary manner.

Certain regions of the genome known as CpG islands or CGIs are segments of DNA where cytosine nucleotides are followed by guanine nucleotides in the linear sequence of bases along the 5' to 3' direction. These are primarily promoter-associated genomic regions and are mostly unmethylated within otherwise highly methylated mammalian genomes. The mechanisms by which CGIs are protected from de novo methylation have not been clarified.

Investigators at the Salk Institute for Biological Studies recently developed a new technique that allowed them to methylate CGIs in stem cells derived from normal or cancerous starting material or from patients suffering from Angelman syndrome (AS), a rare neurodegenerative disorder characterized by aberrant DNA methylation, which causes a loss of the ubiquitin-protein ligase E3A (UBE3A) enzyme in neurons.

They reported in the May 5, 2017, issue of the journal Science that by inserting a segment of CpG-free DNA into targeted CGIs, they were able to induce de novo methylation of the entire CGI in human pluripotent stem cells (PSCs). The methylation status was stably maintained even after the CpG-free DNA was removed, and remained despite the cells being passaged extensively and differentiated.

By targeting the DNA mismatch repair gene MLH1 (mutL homolog 1), the investigators generated a PSC model of a cancer-related epigenetic mutation. In addition, they corrected the DNA methylation in induced PSCs derived from an Angelman syndrome patient and restored UBE3A protein levels in AS neuronal cells grown in culture.

"We are excited at how many new avenues this work opens up for understanding disease processes and developing effective new therapies," said senior author Dr. Juan Carlos Izpisua Belmonte, a professor in the gene expression laboratories at the Salk Institute for Biological Studies. "It was a giant step to discover how to edit the genome--this technology to edit the epigenome is another leap forward."

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.